Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets

Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and... AbstractModified release of furosemide from tablet formulations is preferred by patients, because of physiological problems, acute diuresis being the most serious, compared to the forms designed for immediate release. With this in view, we aimed at achieving furosemide’s longer gastric retention and waste minimization by preparing matrix and compression coated tablets incorporating different grades of Eudragit® and poly(ethylene oxide) (PEO), polyvinylpyrrolidone (PVP) and lactose monohydrate. Dissolution profiles of the new formulations were compared with that of the main stream drug Lasix®, 40 mg tablets. The results indicate that the use of Eudragit® in conjunction with either PVP or lactose monohydrate led to a slower release rate in the intestinal fluids compared to Lasix®. Moreover, furosemide release in the intestinal pH from matrix tablets and compression coated tablets was not noticeably different. Formulations incorporating PEO led to sustained release, in intestinal fluids, which depended on the molecular weight of PEO. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Pharmaceutica de Gruyter

Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets

Download PDF
13 pages

Loading next page...
 
/lp/de-gruyter/modified-release-of-furosemide-from-eudragits-and-poly-ethylene-oxide-sWcVY0DYEi

References (43)

Publisher
de Gruyter
Copyright
© 2020 Marilena Vlachou et al., published by Sciendo
ISSN
1846-9558
eISSN
1846-9558
DOI
10.2478/acph-2020-0010
Publisher site
See Article on Publisher Site

Abstract

AbstractModified release of furosemide from tablet formulations is preferred by patients, because of physiological problems, acute diuresis being the most serious, compared to the forms designed for immediate release. With this in view, we aimed at achieving furosemide’s longer gastric retention and waste minimization by preparing matrix and compression coated tablets incorporating different grades of Eudragit® and poly(ethylene oxide) (PEO), polyvinylpyrrolidone (PVP) and lactose monohydrate. Dissolution profiles of the new formulations were compared with that of the main stream drug Lasix®, 40 mg tablets. The results indicate that the use of Eudragit® in conjunction with either PVP or lactose monohydrate led to a slower release rate in the intestinal fluids compared to Lasix®. Moreover, furosemide release in the intestinal pH from matrix tablets and compression coated tablets was not noticeably different. Formulations incorporating PEO led to sustained release, in intestinal fluids, which depended on the molecular weight of PEO.

Journal

Acta Pharmaceutica – de Gruyter

Published: Mar 1, 2020

Keywords: matrix tablets; compression coated tablets; furosemide; Eudragit ®; poly(ethylene oxide); polyvinylpyrrolidone

There are no references for this article.